Skip to main content

Xultophy® 100/3.6 (insulin degludec and liraglutide injection)

Xultophy® 100/3.6 (insulin degludec and liraglutide injection) is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Search for Letters

Find documents for this product by entering your search terms in the box below.

 

Text: double click to edit.

Have a Question?

Request information directly from the Novo Nordisk
Medical Information department.